NCT03983057 2026-02-11
Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer
Zhejiang University
Phase 2 Completed
Clinical Trials
20 trialsNCT02964078 2026-02-10
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT06493240 2025-11-25
NLCCRIT-LARC
Peking University People's Hospital
Phase 2 Completed
NCT04191421 2025-08-22
Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer
Emory University
Phase 1/2 Completed
NCT04821765 2025-05-30
Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Completed
NCT04581343 2025-05-04
PanCAN-SR1
Pancreatic Cancer Action Network
Phase 1 Completed
NCT04518280 2025-01-17
TORCH
Fudan University
Phase 2 Completed
NCT03874897 2024-04-30
Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.
Peking University
Phase 1 Completed
NCT06298123 2024-03-07
Postoperative Adjuvant Immunotherapy for Hepatocellular Carcinoma: Risk Factor Analysis and Prognostic Modelling
Tongji Hospital
Completed
NCT03757858 2024-02-07
Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases
Capital Medical University
Phase 1/2 Completed
NCT02658981 2023-10-06
Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT06022692 2023-09-05
HEAIS001
Zhejiang Hospital
Phase 1/2 Completed
NCT01176474 2023-07-19
Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT04793815 2023-06-29
Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE)
Centre hospitalier de l'Université de Montréal (CHUM)
Phase NA Completed
NCT01176461 2023-01-18
Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT03609424 2023-01-03
PDR001 Plus Imatinib for Metastatic or Unresectable GIST
Asan Medical Center
Phase 1/2 Completed
NCT02112032 2021-05-05
Treatment of Advanced Melanoma With MK-3475 and Peginterferon
University of Pittsburgh
Phase 1 Completed
NCT02677155 2021-03-01
Lymvac-2
Oslo University Hospital
Phase 2 Completed
NCT03222440 2019-12-04
Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCC
Tianjin Medical University Cancer Institute and Hospital
Phase NA Completed
NCT02331368 2018-07-27
Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma
University of Michigan Rogel Cancer Center
Phase 2 Completed